class InnovativeOncologyCombinationDesign:
    """
    Reusable framework for designing innovative combination therapy protocols
    for refractory cancers. Developed through GBM research, generalizable.
    """
    
    # === TIER RANKING METHODOLOGY ===
    TIER_CRITERIA = {
        'clinical_evidence': {
            'weight': 0.30,
            'metrics': ['phase_2_3_results', 'overall_survival_benefit', 'durable_response_rate'],
            'data_sources': ['clinicaltrials.gov', 'ASCO_abstracts', 'published_trials']
        },
        'combinatorial_potential': {
            'weight': 0.30,
            'metrics': ['mechanistic_complementarity', 'sequential_feasibility', 'synergy_evidence'],
            'assessment': 'Does adding this modality address a distinct resistance mechanism?'
        },
        'mechanistic_strength': {
            'weight': 0.20,
            'metrics': ['target_validity', 'pathway_coverage', 'resistance_overcoming'],
            'assessment': 'Does the mechanism directly address known tumor escape pathways?'
        },
        'practical_feasibility': {
            'weight': 0.20,
            'metrics': ['manufacturing_readiness', 'delivery_accessibility', 'regulatory_pathway_clarity'],
            'assessment': 'Can this be implemented in multi-center trials within 3-5 years?'
        }
    }
    
    # === GBM-SPECIFIC TIER RANKINGS (2025) ===
    GBM_TIERS = {
        'Tier_1_Highest_Evidence_Combinatorial_Value': [
            {
                'modality': 'Oncolytic_viruses',
                'representatives': ['DNX-2401', 'G207', 'teserpaturev'],
                'key_evidence': 'DNX-2401 phase_1_20pct_durable_response_phase_2_combination_ongoing',
                'combinatorial_value': 'Converts_immunosuppressive_microenvironment_direct_tumor_killing_immunogenic_cell_death',
                'optimal_role': 'PRIMING_agent_delivered_after_BBB_disruption'
            },
            {
                'modality': 'Focused_ultrasound_BBB_disruption',
                'representatives': ['ExAblate_Neuro', 'NaviFUS'],
                'key_evidence': 'Phase_1_2_safety_demonstrated_enhanced_drug_delivery_5_10x',
                'combinatorial_value': 'Enables_delivery_of_otherwise_excluded_therapeutics_temporal_window_4_6_hours',
                'optimal_role': 'ENABLING_agent_first_in_sequence'
            },
            {
                'modality': 'CAR_T_cells_with_BBB_enhancement',
                'representatives': ['IL13Ralpha2_CAR_T', 'HER2_CAR_T', 'EGFRvIII_CAR_T'],
                'key_evidence': 'Case_reports_dramatic_responses_phase_1_trials_ongoing',
                'combinatorial_value': 'Targets_specific_antigens_can_be_combined_with_BBB_disruption_for_delivery',
                'optimal_role': 'TARGETING_agent_for_defined_antigen_profiles'
            }
        ],
        'Tier_2_Promising_Emerging_Evidence': [
            {'modality': 'Nanoparticle_delivery_systems', 'role': 'Drug_carrier_enabling_BBB_crossing'},
            {'modality': 'Checkpoint_inhibitors', 'role': 'Maintenance_after_immune_priming_NOT_standalone'},
            {'modality': 'Neoantigen_vaccines', 'role': 'Personalized_immune_reinforcement'}
        ],
        'Tier_3_Early_Stage_Supplementary': [
            {'modality': 'Cancer_stem_cell_targeting', 'role': 'Addresses_recurrence_mechanism_early_stage'},
            {'modality': 'Standalone_checkpoint_inhibitors', 'role': 'Insufficient_alone_in_GBM_immunosuppressive_context'}
        ]
    }
    
    # === SEQUENTIAL COMBINATION DESIGN PRINCIPLES ===
    COMBINATION_DESIGN_PRINCIPLES = {
        'principle_1_address_all_resistance': {
            'description': 'GBM_resistance_is_multi_factorial_BB_heterogeneity_AND_immunosuppression_AND_stem_cells',
            'design_implication': 'Any_effective_regimen_must_address_at_least_2_of_3_simultaneously'
        },
        'principle_2_temporal_sequencing': {
            'description': 'Drug_delivery_and_immune_activation_have_optimal_temporal_windows',
            'design_implication': 'Sequence_matters_BBB_disruption_before_virus_before_checkpoint_inhibitor'
        },
        'principle_3_biomarker_guided_adaptation': {
            'description': 'GBM_molecular_heterogeneity_requires_patient_stratification',
            'design_implication': 'MGMT_status_IDH_status_subtype_classification_guide_treatment_selection'
        },
        'principle_4_priming_before_maintenance': {
            'description': 'Immunosuppressive_TME_must_be_converted_before_checkpoint_inhibition_works',
            'design_implication': 'Oncolytic_virus_or_other_priming_before_PDL1_CTLA4_inhibitors'
        }
    }
    
    # === GLIO-SEQ-01 PROTOCOL SUMMARY ===
    GLIO_SEQ_01 = {
        'title': 'Phase_II_Trial_Sequential_Focused_Ultrasound_Oncolytic_Virus_Anti_PD1_GBM',
        'sequence': [
            {'phase': 'Surgical_resection', 'timing': 'Day_0', 'details': 'Maximal_safe_resection_plus_tumor_tissue_banking'},
            {'phase': 'Stupp_protocol_concurrent', 'timing': 'Weeks_2_7', 'details': 'Standard_radiation_plus_temozolomide_baseline'},
            {'phase': 'FUS_BBB_disruption', 'timing': 'Weeks_8_11', 'details': '3_sessions_2_weeks_apart_4_6_hour_drug_delivery_window'},
            {'phase': 'Oncolytic_virus_delivery', 'timing': 'Weeks_8_11_post_FUS', 'details': 'DNX_2401_or_similar_within_FUS_window'},
            {'phase': 'Anti_PD1_maintenance', 'timing': 'Week_12_onward', 'details': 'Nivolumab_or_pembrolizumab_after_immune_priming_confirmed'}
        ],
        'biomarker_stratification': {
            'Cohort_A': 'MGMT_methylated_IDH_wildtype_classical_subtype',
            'Cohort_B': 'MGMT_unmethylated_IDH_wildtype_mesenchymal_subtype',
            'Cohort_C': 'IDH_mutant_secondary_GBM'
        },
        'primary_endpoints': ['PFS_at_6_months', 'OS_at_12_months'],
        'key_translational_endpoints': ['T_cell_infiltration_change', 'PD_L1_expression_dynamics', 'viral_replication_confirmation']
    }
    
    # === REGULATORY NAVIGATION FRAMEWORK ===
    REGULATORY_FRAMEWORK = {
        'FDA_pathway': 'Office_of_Combination_Products_OCP',
        'designation_strategy': 'Breakthrough_Therapy_Designation_for_GBM',
        'key_arguments': [
            'Serious_condition_with_unmet_medical_need',
            'Preliminary_clinical_evidence_of_substantial_improvement',
            'Sequential_rather_than_concurrent_reduces_interaction_complexity'
        ],
        'manufacturing_challenges': [
            'Viral_vector_GMP_manufacturing_lead_time_6_12_months',
            'FUS_device_multi_center_standardization',
            'Coordinating_biologic_device_drug_regulatory_requirements'
        ],
        'implementation_logistics': [
            'FUS_equipment_requires_MRI_guided_systems_not_universally_available',
            'Timing_coordination_between_FUS_and_viral_delivery_critical',
            'Multi_center_harmonization_of_FUS_parameters'
        ]
    }
    
    # === GENERALIZABLE METHOD ===
    @classmethod
    def design_combination_protocol(cls, cancer_type, known_resistance_mechanisms, available_modalities):
        """
        Generalized method for designing sequential combination protocols.
        Input: cancer type, resistance mechanisms, available modalities
        Output: Ranked modality combinations, proposed sequence, biomarker strategy
        """
        # Step 1: Map resistance mechanisms
        # Step 2: Score modalities by TIER_CRITERIA
        # Step 3: Identify mechanistic complementarity
        # Step 4: Design temporal sequence based on biological logic
        # Step 5: Define biomarker stratification
        # Step 6: Map regulatory pathway
        return 'combination_protocol_design'
